Document is current

Article History

Received: 9 June 2023

Accepted: 29 November 2023

First Online: 18 January 2024

Declarations

:

: All authors declare: No direct or indirect funding was received by any industry party for the present work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. MB received congress travel expenses from Daiichi Sankyo and personal fees from Amgen, Sanofi-Aventis and Novartis. MR reports personal fees from Allergan, Astra-Zeneca, Bristol-Myers-Squibb, Eli Lilly, Fishawack Group, Gilead Sciences, Intercept Pharma, Inventiva, Novartis, Novo Nordisk, Pfizer, Prosciento, Sanofi US, and Target RWE and investigator-initiated research support from Boehringer-Ingelheim, Nutricia/Danone, and Sanofi-Aventis. SS received honoraria for lectures from Novo Nordisk. GW received congress travel expenses from Abbott. OK reports honoraria for biostatistical education and consulting from Berlin-Chemie.

: Not applicable.

: In the present meta-analysis, no primary patient or animal data were analysed for the submitted work. However, all individual trials included report ethics approval warranting human rights.

: Written informed consent obtained from trial participants.